Stelrad Group (SRAD) Competitors

Dr. Martens (LON:DOCS) and Stelrad Group (LON:SRAD) are both small-cap consumer cyclical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability, community ranking and risk.

Is DOCS or SRAD more profitable?

Dr. Martens has a net margin of 7.89% compared to Stelrad Group's net margin of 5.25%. Stelrad Group's return on equity of 28.08% beat Dr. Martens' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Martens	7.89%	18.91%	8.12%
Stelrad Group	5.25%	28.08%	7.46%

Does the MarketBeat Community believe in DOCS or SRAD?

Dr. Martens received 11 more outperform votes than Stelrad Group when rated by MarketBeat users.

Company	Underperform	Outperform
Dr. Martens	Outperform Votes 11 91.67%	Underperform Votes 1 8.33%
Stelrad Group	N/A	N/A

Does the media refer more to DOCS or SRAD?

In the previous week, Dr. Martens had 1 more articles in the media than Stelrad Group. MarketBeat recorded 1 mentions for Dr. Martens and 0 mentions for Stelrad Group. Stelrad Group's average media sentiment score of 1.08 beat Dr. Martens' score of -0.01 indicating that Stelrad Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Dr. Martens	Neutral
Stelrad Group	Positive

Which has higher earnings & valuation, DOCS or SRAD?

Dr. Martens has higher revenue and earnings than Stelrad Group. Dr. Martens is trading at a lower price-to-earnings ratio than Stelrad Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Martens	£874.20M	0.61	£68.97M	£7.05	7.79
Stelrad Group	£306.97M	0.58	£16.13M	£11.64	11.46

Which has more risk & volatility, DOCS or SRAD?

Dr. Martens has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Stelrad Group has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500.

Do insiders & institutionals have more ownership in DOCS or SRAD?

69.5% of Dr. Martens shares are held by institutional investors. Comparatively, 35.5% of Stelrad Group shares are held by institutional investors. 4.4% of Dr. Martens shares are held by company insiders. Comparatively, 64.4% of Stelrad Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Is DOCS or SRAD a better dividend stock?

Dr. Martens pays an annual dividend of GBX 3 per share and has a dividend yield of 5.5%. Stelrad Group pays an annual dividend of GBX 8 per share and has a dividend yield of 6.0%. Dr. Martens pays out 42.5% of its earnings in the form of a dividend. Stelrad Group pays out 68.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Dr. Martens beats Stelrad Group on 9 of the 16 factors compared between the two stocks.